Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

39.44 +0.48 (+1.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
A Glimpse Into The Expert Outlook On Legend Biotech Through 6 Analysts
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Is Legend Biotech Gaining or Losing Market Support?
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday
Via Benzinga
What Does the Market Think About Legend Biotech?
Via Benzinga
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
Is Legend Biotech Gaining or Losing Market Support?
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
Via Benzinga
Where Legend Biotech Stands With Analysts
Via Benzinga
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
Via Benzinga
Breaking Down Legend Biotech: 9 Analysts Share Their Views
Via Benzinga
(LEGN) - Analyzing Legend Biotech's Short Interest
Via Benzinga
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
5 Analysts Have This To Say About Legend Biotech
Via Benzinga
What Does the Market Think About Legend Biotech?
Via Benzinga
Demystifying Legend Biotech: Insights From 5 Analyst Reviews
Via Benzinga
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Earnings Scheduled For March 11, 2025
Via Benzinga
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.